bupropion has been researched along with Weight Gain in 43 studies
Bupropion: A propiophenone-derived antidepressant and antismoking agent that inhibits the uptake of DOPAMINE.
bupropion : An aromatic ketone that is propiophenone carrying a tert-butylamino group at position 2 and a chloro substituent at position 3 on the phenyl ring.
Weight Gain: Increase in BODY WEIGHT over existing weight.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A combination of sustained release (SR) naltrexone (32 mg/day) and bupropion SR (360 mg/day) plus behavioral counseling was evaluated for the treatment of smoking cessation and mitigation of nicotine withdrawal and weight gain." | 9.14 | An open-label study of naltrexone and bupropion combination therapy for smoking cessation in overweight and obese subjects. ( Billes, SK; Dunayevich, E; Erickson, JS; Katz, BB; Oskooilar, N; Tollefson, G; Wilcox, CS, 2010) |
| "To examine the effectiveness of bupropion in reducing bodyweight gained during treatment with olanzapine." | 9.12 | Bupropion treatment of olanzapine-associated weight gain: an open-label, prospective trial. ( Foust, MS; Gadde, KM; Zhang, W, 2006) |
| "Studies undertaken in academic settings have shown that bupropion hydrochloride can double the odds of smoking cessation compared with placebo." | 9.12 | A double-blind, placebo-controlled, randomized trial of bupropion for smoking cessation in primary care. ( Apolone, G; Clivio, L; Compagnoni, A; Fossati, R; Garattini, S; La Vecchia, C; Mangano, S; Negri, E, 2007) |
| "To determine whether bupropion SR, in combination with counselling, is effective for smoking cessation in a multi-country study." | 9.10 | A multicentre, randomized, double-blind, placebo-controlled, 1-year study of bupropion SR for smoking cessation. ( Hider, A; Hjalmarson, A; Lebargy, F; Sweet, R; Tonstad, S; Townsend, J; Tønnesen, P; Van Spiegel, PI, 2003) |
| "Treatment with sustained-release bupropion alone or in combination with a nicotine patch resulted in significantly higher long-term rates of smoking cessation than use of either the nicotine patch alone or placebo." | 9.09 | A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. ( Baker, TB; Daughton, DM; Doan, K; Fiore, MC; Hughes, AR; Johnston, JA; Jorenby, DE; Leischow, SJ; Muramoto, ML; Nides, MA; Rennard, SI; Smith, SS, 1999) |
| "In persons who stopped smoking with 7 weeks of bupropion treatment, sustained-release bupropion for 12 months delayed smoking relapse and resulted in less weight gain." | 9.09 | Sustained-release bupropion for pharmacologic relapse prevention after smoking cessation. a randomized, controlled trial. ( Buist, AS; Durcan, MJ; Gonzales, D; Hays, JT; Hurt, RD; Johnston, JA; Niaura, R; Rigotti, NA; Sachs, DP; White, JD; Wolter, TD, 2001) |
| "A sustained-release form of bupropion was effective for smoking cessation and was accompanied by reduced weight gain and minimal side effects." | 9.08 | A comparison of sustained-release bupropion and placebo for smoking cessation. ( Croghan, IT; Dale, LC; Glover, ED; Glover, PN; Hurt, RD; Johnston, JA; Khayrallah, MA; Offord, KP; Sachs, DP; Schroeder, DR; Sullivan, CR; Sullivan, PM, 1997) |
| " Melatonin, liraglutide, and naltrexone/bupropion are examples of drugs with different mechanisms of action that have favorable effects on obesity or medication-related weight gain." | 8.91 | Melatonin, Liraglutide, and Naltrexone/Bupropion for the Treatment of Obesity and Medication-Related Weight Gain. ( Howland, RH, 2015) |
| " [symbol: see text]Bupropion (Zyban-GlaxoWellcome) has recently been licensed "as an aid to smoking cessation in combination with motivational support"." | 8.80 | Bupropion to aid smoking cessation. ( , 2000) |
| " This investigation was an open label study of naltrexone hydrochloride (25 mg/day) in combination with sustained-release (SR) bupropion hydrochloride (300 mg/day) for smoking cessation and minimization of post-quit weight gain in weight-concerned smokers." | 7.74 | A preliminary investigation of naltrexone augmentation of bupropion to stop smoking with less weight gain. ( Leary, V; Meandzija, B; O'Malley, SS; Salovey, P; Toll, BA; Wu, R, 2008) |
| "Insulin resistance was also assessed at the end." | 6.71 | Weight gain and cardiovascular risk factors during smoking cessation with bupropion or nicotine. ( Alvarez, F; Botella-Carretero, JI; Cantarero, M; Escobar-Morreale, HF; García, G; Martín, I; Valero, AM; Varela, C, 2004) |
| "A combination of sustained release (SR) naltrexone (32 mg/day) and bupropion SR (360 mg/day) plus behavioral counseling was evaluated for the treatment of smoking cessation and mitigation of nicotine withdrawal and weight gain." | 5.14 | An open-label study of naltrexone and bupropion combination therapy for smoking cessation in overweight and obese subjects. ( Billes, SK; Dunayevich, E; Erickson, JS; Katz, BB; Oskooilar, N; Tollefson, G; Wilcox, CS, 2010) |
| "To examine the effectiveness of bupropion in reducing bodyweight gained during treatment with olanzapine." | 5.12 | Bupropion treatment of olanzapine-associated weight gain: an open-label, prospective trial. ( Foust, MS; Gadde, KM; Zhang, W, 2006) |
| "This study evaluated the ability of polymorphisms in five candidate genes to predict weight gain among patients taking bupropion or placebo in a smoking cessation trial." | 5.12 | No evidence for a major role of polymorphisms during bupropion treatment. ( Allison, DB; Berrettini, WH; Hu, J; Lerman, C; Pinto, A; Redden, DT; Restine, SL; Shields, PG, 2006) |
| "Studies undertaken in academic settings have shown that bupropion hydrochloride can double the odds of smoking cessation compared with placebo." | 5.12 | A double-blind, placebo-controlled, randomized trial of bupropion for smoking cessation in primary care. ( Apolone, G; Clivio, L; Compagnoni, A; Fossati, R; Garattini, S; La Vecchia, C; Mangano, S; Negri, E, 2007) |
| "Sustained-release bupropion is efficacious as an aid to smoking cessation in European smokers." | 5.11 | Efficacy of bupropion and predictors of successful outcome in a sample of French smokers: a randomized placebo-controlled trial. ( Aubin, HJ; Berlin, I; Bidaut-Mazel, C; Chemali-Hudry, J; Lagrue, G; Lebargy, F, 2004) |
| "To determine whether bupropion SR, in combination with counselling, is effective for smoking cessation in a multi-country study." | 5.10 | A multicentre, randomized, double-blind, placebo-controlled, 1-year study of bupropion SR for smoking cessation. ( Hider, A; Hjalmarson, A; Lebargy, F; Sweet, R; Tonstad, S; Townsend, J; Tønnesen, P; Van Spiegel, PI, 2003) |
| "Treatment with sustained-release bupropion alone or in combination with a nicotine patch resulted in significantly higher long-term rates of smoking cessation than use of either the nicotine patch alone or placebo." | 5.09 | A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. ( Baker, TB; Daughton, DM; Doan, K; Fiore, MC; Hughes, AR; Johnston, JA; Jorenby, DE; Leischow, SJ; Muramoto, ML; Nides, MA; Rennard, SI; Smith, SS, 1999) |
| "In persons who stopped smoking with 7 weeks of bupropion treatment, sustained-release bupropion for 12 months delayed smoking relapse and resulted in less weight gain." | 5.09 | Sustained-release bupropion for pharmacologic relapse prevention after smoking cessation. a randomized, controlled trial. ( Buist, AS; Durcan, MJ; Gonzales, D; Hays, JT; Hurt, RD; Johnston, JA; Niaura, R; Rigotti, NA; Sachs, DP; White, JD; Wolter, TD, 2001) |
| "A sustained-release form of bupropion was effective for smoking cessation and was accompanied by reduced weight gain and minimal side effects." | 5.08 | A comparison of sustained-release bupropion and placebo for smoking cessation. ( Croghan, IT; Dale, LC; Glover, ED; Glover, PN; Hurt, RD; Johnston, JA; Khayrallah, MA; Offord, KP; Sachs, DP; Schroeder, DR; Sullivan, CR; Sullivan, PM, 1997) |
| " This paper reviews the prevalence of sexual dysfunction, weight gain and emotional detachment during SSRI treatment, the profile of bupropion for each of these events and the ability of bupropion to reverse them." | 4.84 | Review: Bupropion and SSRI-induced side effects. ( Demyttenaere, K; Jaspers, L, 2008) |
| " Bupropion is less likely than other antidepressants to cause weight gain and sexual dysfunction, the 2 side effects that are of greatest concern to patients and that have the greatest impact on long-term compliance." | 4.82 | Why isn't bupropion the most frequently prescribed antidepressant? ( Attiullah, N; Baymiller, S; Berlowitz, SL; Boland, RJ; Chelminski, I; Friedman, M; Posternak, MA; Rahman, S; Singer, S; Uy, KK; Zimmerman, M, 2005) |
| " [symbol: see text]Bupropion (Zyban-GlaxoWellcome) has recently been licensed "as an aid to smoking cessation in combination with motivational support"." | 4.80 | Bupropion to aid smoking cessation. ( , 2000) |
| "While patients using bupropion gained slightly less weight compared to those using varenicline, type of smoking cessation medication was not a significant predictor of weight change in the multivariate linear regression model." | 3.83 | Comparative Effectiveness of Smoking Cessation Medications to Attenuate Weight Gain Following Cessation. ( Abughosh, S; Chen, H; Essien, EJ; Johnson, ML; Peters, RJ; Wang, X; Yang, M, 2016) |
| "Compared with citalopram, in models adjusted for sociodemographic and clinical features, significantly decreased rate of weight gain was observed among individuals treated with bupropion (β [SE]: -0." | 3.80 | An electronic health records study of long-term weight gain following antidepressant use. ( Blumenthal, SR; Castro, VM; Churchill, SE; Clements, CC; Erb, JL; Fava, M; Kohane, IS; Murphy, SN; Perlis, RH; Rosenfield, HR; Smoller, JW; Weilburg, JB, 2014) |
| " Anxiety levels, which are greater in the first few weeks after cessation, do not explain weight variation, which is more related to the metabolic effects of nicotine rather than to psychological variables." | 3.74 | [Weight gain and anxiety levels in recent ex-smokers]. ( Beamonte, A; Gargallo, P; Jiménez-Muro, A; Marqueta, A; Nerín, I, 2007) |
| " This investigation was an open label study of naltrexone hydrochloride (25 mg/day) in combination with sustained-release (SR) bupropion hydrochloride (300 mg/day) for smoking cessation and minimization of post-quit weight gain in weight-concerned smokers." | 3.74 | A preliminary investigation of naltrexone augmentation of bupropion to stop smoking with less weight gain. ( Leary, V; Meandzija, B; O'Malley, SS; Salovey, P; Toll, BA; Wu, R, 2008) |
| "Insulin resistance was also assessed at the end." | 2.71 | Weight gain and cardiovascular risk factors during smoking cessation with bupropion or nicotine. ( Alvarez, F; Botella-Carretero, JI; Cantarero, M; Escobar-Morreale, HF; García, G; Martín, I; Valero, AM; Varela, C, 2004) |
| "Weight gain is cited as a primary reason for not trying to quit smoking." | 2.42 | Smoking cessation and weight gain. ( Fernández Pinilla, MC; Fernández-Cruz, A; Filozof, C, 2004) |
| "Anecdotal reports have suggested that the long-term use of selective serotonin reuptake inhibitors (SSRIs) may be associated with significant weight gain, sexual dysfunction, drug interactions, and discontinuation symptoms." | 2.41 | Long-term side effects of newer-generation antidepressants: SSRIS, venlafaxine, nefazodone, bupropion, and mirtazapine. ( Gupta, S; Masand, PS, 2002) |
| "Study data demonstrate that seizure incidence, which is a concern with high-dose IR, is substantially lower with the new SR formulation." | 2.40 | Bupropion sustained release: side effect profile. ( Settle, EC, 1998) |
| "Despite the superior side effect profile of the newer antidepressants over the tricyclics and monoamine oxidase inhibitors, all newer antidepressants are associated with a wide array of side effects." | 1.31 | The pharmacologic management of SSRI-induced side effects: a survey of psychiatrists. ( Dording, CM; Fava, M; Gordon, J; Kornbluh, R; Mischoulon, D; Nierenberg, AA; Petersen, TJ; Rosenbaum, JE, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (16.28) | 18.2507 |
| 2000's | 27 (62.79) | 29.6817 |
| 2010's | 9 (20.93) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sobell, MB | 1 |
| Peterson, AL | 1 |
| Sobell, LC | 1 |
| Brundige, A | 1 |
| Hunter, CM | 2 |
| Goodie, JL | 1 |
| Agrawal, S | 1 |
| Hrysko-Mullen, AS | 1 |
| Isler, WC | 1 |
| Hou, YC | 1 |
| Lai, CH | 1 |
| Blumenthal, SR | 1 |
| Castro, VM | 1 |
| Clements, CC | 1 |
| Rosenfield, HR | 1 |
| Murphy, SN | 1 |
| Fava, M | 2 |
| Weilburg, JB | 1 |
| Erb, JL | 1 |
| Churchill, SE | 1 |
| Kohane, IS | 1 |
| Smoller, JW | 1 |
| Perlis, RH | 1 |
| Howland, RH | 1 |
| Yang, M | 1 |
| Chen, H | 1 |
| Johnson, ML | 1 |
| Essien, EJ | 1 |
| Peters, RJ | 1 |
| Wang, X | 1 |
| Abughosh, S | 1 |
| Igel, LI | 1 |
| Kumar, RB | 1 |
| Saunders, KH | 1 |
| Aronne, LJ | 1 |
| Kapoor, S | 1 |
| Iñiguez, SD | 1 |
| Warren, BL | 1 |
| Parise, EM | 1 |
| Alcantara, LF | 1 |
| Schuh, B | 1 |
| Maffeo, ML | 1 |
| Manojlovic, Z | 1 |
| Bolaños-Guzmán, CA | 1 |
| Etter, JF | 1 |
| Huguelet, P | 1 |
| Perneger, TV | 1 |
| Cornuz, J | 1 |
| Nanchen, D | 1 |
| Willi, C | 1 |
| Peytremann-Bridevaux, I | 1 |
| Burnand, B | 1 |
| Walther, MR | 1 |
| Wilcox, CS | 1 |
| Oskooilar, N | 1 |
| Erickson, JS | 1 |
| Billes, SK | 1 |
| Katz, BB | 1 |
| Tollefson, G | 1 |
| Dunayevich, E | 1 |
| Kaplan, LM | 1 |
| Levine, MD | 1 |
| Cheng, Y | 1 |
| Kalarchian, MA | 1 |
| Perkins, KA | 1 |
| Marcus, MD | 1 |
| Dording, CM | 1 |
| Mischoulon, D | 1 |
| Petersen, TJ | 1 |
| Kornbluh, R | 1 |
| Gordon, J | 1 |
| Nierenberg, AA | 1 |
| Rosenbaum, JE | 1 |
| Masand, PS | 1 |
| Gupta, S | 1 |
| Tønnesen, P | 1 |
| Tonstad, S | 2 |
| Hjalmarson, A | 1 |
| Lebargy, F | 2 |
| Van Spiegel, PI | 1 |
| Hider, A | 1 |
| Sweet, R | 1 |
| Townsend, J | 1 |
| Botella-Carretero, JI | 1 |
| Escobar-Morreale, HF | 1 |
| Martín, I | 1 |
| Valero, AM | 1 |
| Alvarez, F | 1 |
| García, G | 1 |
| Varela, C | 1 |
| Cantarero, M | 1 |
| Filozof, C | 1 |
| Fernández Pinilla, MC | 1 |
| Fernández-Cruz, A | 1 |
| Johnston, JA | 4 |
| Aubin, HJ | 1 |
| Berlin, I | 1 |
| Bidaut-Mazel, C | 1 |
| Chemali-Hudry, J | 1 |
| Lagrue, G | 1 |
| Gołecki, M | 1 |
| Zimmerman, M | 1 |
| Posternak, MA | 1 |
| Attiullah, N | 1 |
| Friedman, M | 1 |
| Boland, RJ | 1 |
| Baymiller, S | 1 |
| Berlowitz, SL | 1 |
| Rahman, S | 1 |
| Uy, KK | 1 |
| Singer, S | 1 |
| Chelminski, I | 1 |
| Menaster, MJ | 1 |
| Gadde, KM | 1 |
| Zhang, W | 1 |
| Foust, MS | 1 |
| Hu, J | 1 |
| Redden, DT | 1 |
| Berrettini, WH | 1 |
| Shields, PG | 1 |
| Restine, SL | 1 |
| Pinto, A | 1 |
| Lerman, C | 1 |
| Allison, DB | 1 |
| Nerín, I | 1 |
| Beamonte, A | 1 |
| Gargallo, P | 1 |
| Jiménez-Muro, A | 1 |
| Marqueta, A | 1 |
| Ramseier, CA | 1 |
| Bornstein, MM | 1 |
| Saxer, UP | 1 |
| Klingler, K | 1 |
| Walter, C | 1 |
| Toll, BA | 1 |
| Leary, V | 1 |
| Wu, R | 1 |
| Salovey, P | 1 |
| Meandzija, B | 1 |
| O'Malley, SS | 1 |
| Fossati, R | 1 |
| Apolone, G | 1 |
| Negri, E | 1 |
| Compagnoni, A | 1 |
| La Vecchia, C | 1 |
| Mangano, S | 1 |
| Clivio, L | 1 |
| Garattini, S | 1 |
| Demyttenaere, K | 1 |
| Jaspers, L | 1 |
| Lief, HI | 1 |
| Hurt, RD | 2 |
| Sachs, DP | 2 |
| Glover, ED | 1 |
| Offord, KP | 1 |
| Dale, LC | 1 |
| Khayrallah, MA | 1 |
| Schroeder, DR | 1 |
| Glover, PN | 1 |
| Sullivan, CR | 1 |
| Croghan, IT | 1 |
| Sullivan, PM | 1 |
| McAfee, T | 1 |
| France, E | 1 |
| Settle, EC | 1 |
| Jorenby, DE | 1 |
| Leischow, SJ | 1 |
| Nides, MA | 1 |
| Rennard, SI | 1 |
| Hughes, AR | 1 |
| Smith, SS | 1 |
| Muramoto, ML | 1 |
| Daughton, DM | 1 |
| Doan, K | 1 |
| Fiore, MC | 1 |
| Baker, TB | 1 |
| Haustein, KO | 2 |
| Hays, JT | 1 |
| Rigotti, NA | 1 |
| Niaura, R | 1 |
| Gonzales, D | 1 |
| Durcan, MJ | 1 |
| Wolter, TD | 1 |
| Buist, AS | 1 |
| White, JD | 1 |
| Croft, H | 1 |
| Houser, TL | 1 |
| Jamerson, BD | 1 |
| Leadbetter, R | 1 |
| Bolden-Watson, C | 1 |
| Donahue, R | 1 |
| Metz, A | 1 |
| Workman, EA | 1 |
| Short, DD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effects of a High Eicosapentaenoic Acid Multinutrient Supplement on Measures of Stress, Anxiety and Depression in Young Adults: a Randomised, Double-blind, Placebo-controlled Trial.[NCT04844034] | 94 participants (Anticipated) | Interventional | 2022-04-19 | Recruiting | |||
| Effects of a Tissue Selective Estrogen Complex (TESC) on Depression and the Neural Reward System in the Perimenopause[NCT03740009] | Phase 4 | 20 participants (Actual) | Interventional | 2019-01-02 | Completed | ||
| WhatsApp Embedded in Routine Service Delivery for Smoking Cessation: Effects on Success Rates in a Randomized Controlled Study[NCT03714971] | 127 participants (Actual) | Interventional | 2017-03-01 | Completed | |||
| Naltrexone & Bupropion to Stop Smoking With Less Weight Gain[NCT00129246] | Phase 1/Phase 2 | 40 participants (Actual) | Interventional | 2004-12-31 | Completed | ||
| Phase II Randomized, Double-Blind Trial of Bupropion Versus Bupropion + Naltrexone for Smoking Cessation[NCT00419731] | Phase 2/Phase 3 | 120 participants (Anticipated) | Interventional | 2006-11-30 | Recruiting | ||
| A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Dose-Ranging Study of 100 or 250 μg of TA-NIC to Assess the Efficacy and Safety of the Vaccine as an Aid to Smoking Cessation[NCT00633321] | Phase 2 | 522 participants (Anticipated) | Interventional | 2007-05-31 | Completed | ||
| The STOP Study: Real World Effectiveness of Zyban Treatment in a Clinical Population[NCT01015170] | Phase 4 | 454 participants (Actual) | Interventional | 2009-10-31 | Completed | ||
| Human Laboratory Study of Varenicline and Bupropion for Nicotine Dependence[NCT00749658] | Phase 2/Phase 3 | 121 participants (Actual) | Interventional | 2008-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The primary outcome measure is functional magnetic resonance imaging (fMRI) data collected during a Monetary Incentive Delay (MID) Task. All participants will complete the fMRI Monetary Incentive Delay (MID) task at baseline and at 3 weeks. During the task, participants need to select the correct response during win and lose conditions by pressing a button on a button box in the MRI. Participant's blood-oxygen-level dependent (BOLD) activation response (A measurement of oxygen level that is released to neurons since areas of the brain that are thought to be more active or involved in certain tasks require more oxygen to perform the tasks.) is measured while they performed the task in MRI scanner." (NCT03740009)
Timeframe: Baseline to 3 weeks
| Intervention | percent signal change (Mean) | |||||
|---|---|---|---|---|---|---|
| Caudate Baseline | Caudate Posttreatment | Nucleus Accumbens Baseline | Nucleus Accumbens Posttreatment | Putamen Baseline | Putamen Posttreatment | |
| Perimenopausal Women, Depressed | .0704 | .0475 | .0623 | .0280 | .0399 | .0408 |
The second primary outcome measure uses the Mood and Anxiety Symptoms Questionnaire - Anhedonic Depression Scale (MASQ-AD) to examine symptom change. All participants will complete the MASQ-AD at each study visit, which measures their current symptoms of depression and anxiety. Scores range from 22 to 110 with lower scores reflecting a better outcome. (NCT03740009)
Timeframe: Baseline, week 2, week 3, week 4 (post treatment)
| Intervention | score on a scale (Mean) | |||
|---|---|---|---|---|
| Baseline Week 1 | Week 2 | Week 3 | Post Treatment Week 4 | |
| Perimenopausal Women, Depressed | 72.1 | 62.4 | 57.2 | 54.5 |
Point prevalence abstinence is defined as the number of patients reporting point prevalence abstinence over the last 7 days. (NCT00129246)
Timeframe: Week 6
| Intervention | participants (Number) |
|---|---|
| Bupropion Only | 8 |
| Naltrexone +Bupropion | 8 |
Smoking cessation is defined as the number of patients that displayed continuous 6-week abstinence from the quit date. (NCT00129246)
Timeframe: Week 6
| Intervention | participants (Number) |
|---|---|
| Bupropion Only | 6 |
| Naltrexone +Bupropion | 6 |
Weight gain for for the entire sample in pounds at 6 weeks. (NCT00129246)
Timeframe: Week 6
| Intervention | lbs (Mean) |
|---|---|
| Bupropion Only | 1.25 |
| Naltrexone +Bupropion | 0.28 |
Weight gain (in pounds) for the patients that were continuously abstinent at 6 weeks. (NCT00129246)
Timeframe: Week 6
| Intervention | lbs (Mean) |
|---|---|
| Bupropion Only | 3.17 |
| Naltrexone +Bupropion | 1.67 |
"Number of participants who report Not Smoking (not even a puff) in past 7 days when asked at week 8" (NCT01015170)
Timeframe: End of Treatment (8 weeks after Zyban start date)
| Intervention | participants (Number) | |
|---|---|---|
| Still smoking | Quit smoking | |
| Nicotine Replacement & Behavioural Support | 109 | 106 |
12 reviews available for bupropion and Weight Gain
| Article | Year |
|---|---|
Melatonin, Liraglutide, and Naltrexone/Bupropion for the Treatment of Obesity and Medication-Related Weight Gain.
Topics: Anti-Obesity Agents; Bupropion; Drug Combinations; Humans; Liraglutide; Melatonin; Naltrexone; Obesi | 2015 |
Practical Use of Pharmacotherapy for Obesity.
Topics: Androgens; Anti-Obesity Agents; Antidepressive Agents; Antihypertensive Agents; Antipsychotic Agents | 2017 |
Pharmacologic therapies for obesity.
Topics: Anti-Obesity Agents; Appetite Depressants; Bariatric Surgery; Benzazepines; Bupropion; Cyclobutanes; | 2010 |
Long-term side effects of newer-generation antidepressants: SSRIS, venlafaxine, nefazodone, bupropion, and mirtazapine.
Topics: Antidepressive Agents, Second-Generation; Bupropion; Cyclohexanols; Drug Interactions; Humans; Mians | 2002 |
Long-term side effects of newer-generation antidepressants: SSRIS, venlafaxine, nefazodone, bupropion, and mirtazapine.
Topics: Antidepressive Agents, Second-Generation; Bupropion; Cyclohexanols; Drug Interactions; Humans; Mians | 2002 |
Long-term side effects of newer-generation antidepressants: SSRIS, venlafaxine, nefazodone, bupropion, and mirtazapine.
Topics: Antidepressive Agents, Second-Generation; Bupropion; Cyclohexanols; Drug Interactions; Humans; Mians | 2002 |
Long-term side effects of newer-generation antidepressants: SSRIS, venlafaxine, nefazodone, bupropion, and mirtazapine.
Topics: Antidepressive Agents, Second-Generation; Bupropion; Cyclohexanols; Drug Interactions; Humans; Mians | 2002 |
Smoking cessation and weight gain.
Topics: Body Composition; Bupropion; Cardiovascular Diseases; Dopamine Uptake Inhibitors; Female; Humans; In | 2004 |
Does bupropion have advantages over other medical therapies in the cessation of smoking?
Topics: Administration, Cutaneous; Aged; Bupropion; Delayed-Action Preparations; Dopamine Uptake Inhibitors; | 2004 |
[Bupropion SR for the therapy of tobacco dependence].
Topics: Bupropion; Delayed-Action Preparations; Dopamine Uptake Inhibitors; Humans; Tobacco Use Disorder; Tr | 2004 |
Why isn't bupropion the most frequently prescribed antidepressant?
Topics: Adult; Ambulatory Care; Antidepressive Agents; Antidepressive Agents, Second-Generation; Bupropion; | 2005 |
Review: Bupropion and SSRI-induced side effects.
Topics: Affective Symptoms; Bupropion; Depression; Dopamine Uptake Inhibitors; Drug Interactions; Drug Thera | 2008 |
Bupropion sustained release: side effect profile.
Topics: Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Bupropion; Delayed-Actio | 1998 |
Pharmacotherapy of nicotine dependence.
Topics: Bupropion; Drug Interactions; Humans; Prognosis; Tobacco Use Disorder; Weight Gain | 2000 |
Bupropion to aid smoking cessation.
Topics: Adult; Aged; Bupropion; Chemotherapy, Adjuvant; Delayed-Action Preparations; Dopamine Uptake Inhibit | 2000 |
16 trials available for bupropion and Weight Gain
| Article | Year |
|---|---|
Reducing alcohol consumption to minimize weight gain and facilitate smoking cessation among military beneficiaries.
Topics: Adult; Alcohol Drinking; Bupropion; Dopamine Uptake Inhibitors; Energy Intake; Female; Humans; Male; | 2017 |
Nicotine gum treatment before smoking cessation: a randomized trial.
Topics: Bupropion; Chewing Gum; Humans; Nicotine; Polymethacrylic Acids; Polyvinyls; Smoking Cessation; Toba | 2009 |
An open-label study of naltrexone and bupropion combination therapy for smoking cessation in overweight and obese subjects.
Topics: Adult; Bupropion; Cotinine; Counseling; Dopamine Uptake Inhibitors; Drug Therapy, Combination; Femal | 2010 |
Dietary intake after smoking cessation among weight-concerned women smokers.
Topics: Body Weight; Bupropion; Diet; Eating; Female; Humans; Smoking; Smoking Cessation; Weight Gain | 2012 |
A multicentre, randomized, double-blind, placebo-controlled, 1-year study of bupropion SR for smoking cessation.
Topics: Adult; Bupropion; Delayed-Action Preparations; Dopamine Uptake Inhibitors; Double-Blind Method; Fema | 2003 |
Weight gain and cardiovascular risk factors during smoking cessation with bupropion or nicotine.
Topics: Administration, Cutaneous; Adult; Aging; Blood Pressure; Bupropion; Cardiovascular Diseases; Diastol | 2004 |
Efficacy of bupropion and predictors of successful outcome in a sample of French smokers: a randomized placebo-controlled trial.
Topics: Adult; Alcohol Drinking; Bupropion; Dopamine Uptake Inhibitors; Double-Blind Method; Female; France; | 2004 |
Bupropion treatment of olanzapine-associated weight gain: an open-label, prospective trial.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Benzodiazepines; Buprop | 2006 |
No evidence for a major role of polymorphisms during bupropion treatment.
Topics: Adult; Bupropion; Dopamine Uptake Inhibitors; Double-Blind Method; Female; Genetic Predisposition to | 2006 |
A double-blind, placebo-controlled, randomized trial of bupropion for smoking cessation in primary care.
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Delayed-Action Preparations; Double-Blin | 2007 |
A comparison of sustained-release bupropion and placebo for smoking cessation.
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Delayed-Action Preparations; Depression; | 1997 |
A comparison of sustained-release bupropion and placebo for smoking cessation.
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Delayed-Action Preparations; Depression; | 1997 |
A comparison of sustained-release bupropion and placebo for smoking cessation.
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Delayed-Action Preparations; Depression; | 1997 |
A comparison of sustained-release bupropion and placebo for smoking cessation.
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Delayed-Action Preparations; Depression; | 1997 |
A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation.
Topics: Administration, Cutaneous; Adult; Antidepressive Agents, Second-Generation; Bupropion; Delayed-Actio | 1999 |
A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation.
Topics: Administration, Cutaneous; Adult; Antidepressive Agents, Second-Generation; Bupropion; Delayed-Actio | 1999 |
A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation.
Topics: Administration, Cutaneous; Adult; Antidepressive Agents, Second-Generation; Bupropion; Delayed-Actio | 1999 |
A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation.
Topics: Administration, Cutaneous; Adult; Antidepressive Agents, Second-Generation; Bupropion; Delayed-Actio | 1999 |
A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation.
Topics: Administration, Cutaneous; Adult; Antidepressive Agents, Second-Generation; Bupropion; Delayed-Actio | 1999 |
A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation.
Topics: Administration, Cutaneous; Adult; Antidepressive Agents, Second-Generation; Bupropion; Delayed-Actio | 1999 |
A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation.
Topics: Administration, Cutaneous; Adult; Antidepressive Agents, Second-Generation; Bupropion; Delayed-Actio | 1999 |
A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation.
Topics: Administration, Cutaneous; Adult; Antidepressive Agents, Second-Generation; Bupropion; Delayed-Actio | 1999 |
A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation.
Topics: Administration, Cutaneous; Adult; Antidepressive Agents, Second-Generation; Bupropion; Delayed-Actio | 1999 |
[Antidepressive drug against nicotine. A method for smoking cessation].
Topics: Administration, Cutaneous; Bupropion; Chewing Gum; Delayed-Action Preparations; Drug Administration | 2000 |
Sustained-release bupropion for pharmacologic relapse prevention after smoking cessation. a randomized, controlled trial.
Topics: Adult; Bupropion; Delayed-Action Preparations; Double-Blind Method; Female; Humans; Male; Middle Age | 2001 |
Summaries for patients. Bupropion to prevent relapse in people who quit cigarette smoking.
Topics: Adult; Bupropion; Delayed-Action Preparations; Female; Humans; Male; Middle Aged; Patient Compliance | 2001 |
Effect on body weight of bupropion sustained-release in patients with major depression treated for 52 weeks.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Body Mass Index; Bupropion; Delay | 2002 |
15 other studies available for bupropion and Weight Gain
| Article | Year |
|---|---|
Bupropion-related weight gain in a fresh depression patient.
Topics: Antidepressive Agents, Second-Generation; Body Mass Index; Bupropion; Depressive Disorder, Major; Fe | 2014 |
An electronic health records study of long-term weight gain following antidepressant use.
Topics: Adult; Amitriptyline; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Bo | 2014 |
Comparative Effectiveness of Smoking Cessation Medications to Attenuate Weight Gain Following Cessation.
Topics: Adult; Bupropion; Female; Humans; Male; Middle Aged; Retrospective Studies; Smoking Cessation; Tobac | 2016 |
Strategies to control antipsychotic-induced weight gain.
Topics: Anti-Obesity Agents; Antipsychotic Agents; Awareness; Body Weight; Bupropion; Clinical Competence; F | 2008 |
Nicotine exposure during adolescence induces a depression-like state in adulthood.
Topics: Aging; Animals; Antidepressive Agents, Second-Generation; Anxiety; Bupropion; Cholinergic Agents; De | 2009 |
[Preventing weight gain in smoking cessation: there is no miracle solution].
Topics: Adult; Bupropion; Dopamine Uptake Inhibitors; Drug Therapy, Combination; Female; Fluoxetine; Humans; | 2009 |
The pharmacologic management of SSRI-induced side effects: a survey of psychiatrists.
Topics: Akathisia, Drug-Induced; Antidepressive Agents, Second-Generation; Bupropion; Critical Pathways; Dat | 2002 |
Weight gain, sexual dysfunction, and bupropion.
Topics: Ambulatory Care; Bupropion; Delayed-Action Preparations; Depressive Disorder; Drug Labeling; Humans; | 2005 |
[Weight gain and anxiety levels in recent ex-smokers].
Topics: Adult; Anxiety; Basal Metabolism; Breath Tests; Bupropion; Carbon Monoxide; Chewing Gum; Feeding Beh | 2007 |
[Tobacco use prevention and cessation in the dental practice].
Topics: Behavior Therapy; Benzazepines; Bupropion; Dentist-Patient Relations; Health Plan Implementation; Hu | 2007 |
A preliminary investigation of naltrexone augmentation of bupropion to stop smoking with less weight gain.
Topics: Adult; Bupropion; Case-Control Studies; Combined Modality Therapy; Dopamine Uptake Inhibitors; Drug | 2008 |
A preliminary investigation of naltrexone augmentation of bupropion to stop smoking with less weight gain.
Topics: Adult; Bupropion; Case-Control Studies; Combined Modality Therapy; Dopamine Uptake Inhibitors; Drug | 2008 |
A preliminary investigation of naltrexone augmentation of bupropion to stop smoking with less weight gain.
Topics: Adult; Bupropion; Case-Control Studies; Combined Modality Therapy; Dopamine Uptake Inhibitors; Drug | 2008 |
A preliminary investigation of naltrexone augmentation of bupropion to stop smoking with less weight gain.
Topics: Adult; Bupropion; Case-Control Studies; Combined Modality Therapy; Dopamine Uptake Inhibitors; Drug | 2008 |
Bupropion treatment of depression to assist smoking cessation.
Topics: Bupropion; Comorbidity; Depressive Disorder; Female; Humans; Smoking; Smoking Cessation; Smoking Pre | 1996 |
Sustained-release bupropion for smoking cessation.
Topics: Bupropion; Dose-Response Relationship, Drug; Smoking Cessation; Weight Gain | 1998 |
Antidepressant drug helps smoking cessation.
Topics: Antidepressive Agents, Second-Generation; Bupropion; Humans; Smoking Cessation; Weight Gain | 1998 |
Bupropion-induced carbohydrate craving and weight gain.
Topics: Adult; Bupropion; Depressive Disorder; Dietary Carbohydrates; Feeding and Eating Disorders; Humans; | 1992 |